Most medical startups fail due diligence because of regulatory blind spots — not because of the technology. Our AI-powered assessment identifies your FDA risks before investors do.
FDA pathway analysis in 48 hours
Identify regulatory red flags before investors do
Match with investors aligned to your thesis
30-minute strategy call included
"The regulatory risk report MedVC.ai provided was the first thing our Series A lead asked for — and we already had it."
Dr. Sarah Chen, MD
CEO, CardioSync Technologies
"We identified two critical FDA submission gaps in our first assessment. Fixed them before our roadshow. Raised $8M."